Structure Therapeutics Inc. (GPCR) Stock Price & Analysis
Structure Therapeutics Inc. (GPCR) closed at USD 21.48 on Wednesday, October 28, 2026, down 0.32% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 21.55; the Oct 28, 2026 session ranged USD 20.5–21.67 on volume of 986,891 shares. Market capitalization is $1.53B, with a 52-week range of USD 20.5–94.9 (NGM). Source: Nexqual, retrieved October 29, 2026 at 01:37 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GPCR.md
Key facts (GPCR)
- Analysts: Buy (mean 1.81 on a 1–5 scale) (16 analysts), mean target USD 107.29 (range 70–145).
- Total return with dividends: 1Y -27.4% vs S&P 500 +13.6%; 5Y -17.4% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.24, revenue estimate $50.0M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GPCR)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Operating income | -$52.6M | -$103M | -$158M | -$177M | -$258M |
| Net income | -$51.3M | -$89.6M | -$123M | -$141M | -$215M |
| EPS (diluted) | -$5.51 | -$0.81 | -$0.78 | -$0.80 | — |
| Free cash flow | -$46.3M | -$81.7M | -$118M | -$226M | -$225M |
| Cash + short-term investments | $90.8M | $467M | $884M | $1.45B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GPCR)
P/B 1.1x · FCF yield -14.66% · Earnings yield -14.03%
Analysts (GPCR)
Consensus Buy (mean 1.81 on a 1–5 scale), 16 analysts; mean target USD 107.29 (low 70, high 145).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Citizens | Reiterated | Market Outperform | $110 |
| 2026-08-07 | Citigroup | Target lowered | Buy | $100 → $97 |
| 2026-08-07 | Citizens | Target lowered | Market Outperform | $113 → $110 |
Total return (dividends reinvested) (GPCR)
| 1Y (from 2025-10-29) | 5Y (from 2023-01-30) | |
|---|---|---|
| Total return | -27.4% | -17.4% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -27.4% | -5.0% |
| Volatility (annualized) | 93.2% | 86.6% |
| Max drawdown | -77.5% (Jan 2026→Oct 2026) | -78.4% (Oct 2023→Mar 2025) |
GPCR earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.49 | −$0.38 | Miss −28.9% | +5.2% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.35 | −$0.31 | Miss −12.9% | -4.3% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | $0.20 | −$0.37 | Beat +$0.57 | -5.3% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.37 | −$0.37 | In line | +2.0% |
| Aug 6, 2025 | — | — | — | — | -2.9% |
| May 8, 2025 | — | — | — | — | -3.9% |
| Feb 27, 2025 | — | — | — | — | +19.5% |
| Nov 13, 2024 | — | — | — | — | +1.9% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
GPCR recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 8, 2026 | 8-K | Regulation FD disclosure; Other material event “ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial. The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamic (PD) effects of ACCG-2671 in 31 healthy adult participants without obesity. A wide range of doses were…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 13.2% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
GPCR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | WuXi | “Our APIs and drug product for our product candidates are currently provided by a supplier, WuXi STA, a subsidiary of WuXi AppTec, and we expect to rely on this supplier for the foreseeable future.” |
| Supplier | Basecamp Bio | “In addition to our technology development and early discovery activities through Basecamp Bio in China, substantially all of our suppliers and clinical trial relationships are located outside the United States.” |
| Customer | EXELIXIS, INC. (EXEL) | “The Company concluded that the sale of such assets should be accounted for under the guidance at ASC 610-20, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets, as this type of transaction did not meet the definition of "ordinary activities" of the Company and Exelixis is not considered a "customer" in this transaction.” |
| Partner | Eli Lilly (LLY) | “We are aware of amylin small molecules in preclinical development by: Eli Lilly, Eccogene, Nxera, Iktos/Cube Biotech strategic collaboration, Alveus Therapeutics and Ambrosia Biosciences.” |
| Partner | Lhotse Bio | “Because we currently rely on Schrödinger for a substantial portion of our discovery capabilities, if Schrödinger delays or fails to perform its obligations under the Lhotse-Schrödinger Agreement or Aconcagua-Schrödinger Agreement, disagrees with our interpretation of the terms of the collaborations or our discovery plan or terminates the Lhotse-Schrödinger Agreement or Aconcagua-Schrödinger Agreement, our pipeline…” |
| Partner | Aconcagua Bio | “Because we currently rely on Schrödinger for a substantial portion of our discovery capabilities, if Schrödinger delays or fails to perform its obligations under the Lhotse-Schrödinger Agreement or Aconcagua-Schrödinger Agreement, disagrees with our interpretation of the terms of the collaborations or our discovery plan or terminates the Lhotse-Schrödinger Agreement or Aconcagua-Schrödinger Agreement, our pipeline…” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name GPCR in their SEC reports
| Relationship to GPCR | Company | Filing | Sentence |
|---|---|---|---|
| partner | Schrodinger, Inc. (SDGR) | 10-K Feb 25, 2026 | “Our current collaborators include, but are not limited to, Ajax Therapeutics, Inc., BMS, Bright Angel Therapeutics Inc., Lilly, Novartis, Otsuka Pharmaceutical Co., Ltd., or Otsuka, Sanofi S.A., and Structure Therapeutics Inc. (formerly ShouTi, Inc.).” |
GPCR company outlook (results filed Aug 6, 2026)
- “Data are expected in Q3 2026. ·”
- “Data are expected in Q4 2026. ·”
- “Data are expected in Q4 2026. ·”
- “Data are expected in Q4 2026.”
Quoted word-for-word from the SEC 8-K results press release.
GPCR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.24 | $-0.19 | −$0.05 | $50.0M | 10 |
| Next quarter (ends Dec 2026) | $-0.49 | $-0.45 | −$0.04 | $0 | 10 |
| Current fiscal year (ends Dec 2026) | $-1.62 | $-1.43 | −$0.19 | $41.7M | 11 |
| Next fiscal year (ends Dec 2027) | $-2.19 | $-2.08 | −$0.11 | $45,450 | 9 |
GPCR options: expected move
Options price a move of about ±19.5% (±$4.20) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 93.8% | ±19.5% |
| Dec 18, 2026 | 51 | 86.4% | ±26.5% |
| Jan 15, 2027 | 79 | 95.2% | ±36.0% |
| Apr 16, 2027 | 170 | 83.7% | ±46.3% |
30-day implied volatility 86.4% vs 52.5% realized over the last 30 trading days. Put/call ratio (volume) 0.19. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 01:37 UTC)
| Price | USD 21.48 |
|---|---|
| Change | ▼ 0.32% (down) |
| Previous Close | USD 21.55 |
| Open | USD 21.29 |
| Day Range | USD 20.5 – 21.67 |
| 52-Week Range | USD 20.5 – 94.9 |
| Volume | 986,891 shares |
| Market Cap | $1.53B |
| Exchange | NGM |
Technical Analysis (GPCR)
Nexqual's technical model rates GPCR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 01:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.11 (oversold) |
| vs SMA50 | Below (USD 34.65) |
| MACD | -3.8 (negative) |
Analyst Ratings (GPCR)
Wall Street analysts rate GPCR "Buy" based on 16 analysts, with a mean price target of USD 107.29 (range USD 70–145), per Nexqual as of October 29, 2026 at 01:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 107.29 |
| High Target | USD 145 |
| Low Target | USD 70 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (GPCR)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $50.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.49 vs est -0.38 ▼ miss |
| 2026-03-31 | USD -0.35 vs est -0.31 ▼ miss |
| 2025-12-31 | USD 0.2 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.37 ▼ miss |
Source: Nexqual, October 29, 2026 at 01:37 UTC.
Financials & Fundamentals (GPCR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -20.21% |
| Debt / Equity | 0 |
| Current Ratio | 20.75 |
| Total Cash | $1.34B |
| Total Debt | $6.23M |
Source: Nexqual, October 29, 2026 at 01:37 UTC.
Financial Health Score (GPCR)
Nexqual rates Structure Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 01:37 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $1.34B cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$222M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -16%, ROA -15.1% (last 4 quarters, SEC) |
Ownership (GPCR)
| Insider Ownership | +3.11% |
|---|---|
| Institutional Ownership | +97.59% |
| Shares Outstanding | 71.31M |
| Float | 55.46M |
| Short % of Float | +13.72% |
Source: Nexqual, October 29, 2026 at 01:37 UTC.
Leadership (GPCR)
Structure Therapeutics Inc. is led by Raymond C. Stevens, CEO & Director, per Nexqual as of October 29, 2026 at 01:37 UTC.
| CEO & Director | Raymond C. Stevens |
|---|---|
| Co- Founder, CFO & Secretary | Jun S. Yoon |
| Chief Technology Officer | Yingli Ma |
| Chief Scientific Officer & GM of Structure Shanghai | Xichen Lin |
| COO & General Counsel | Matthew Lang |
Major Backers & Investors (GPCR)
Notable institutional backers of Structure Therapeutics Inc. include FMR, LLC, Wellington Management, Avoro Capital Advisors LLC, according to Nexqual as of October 29, 2026 at 01:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 11.22% |
| Wellington Management | 10.6% |
| Avoro Capital Advisors LLC | 9.42% |
| Jupiter Topco LLC | 7.48% |
| Deep Track Capital, Lp | 6.81% |
| BVF Inc. | 4.84% |
| Fidelity | 4.09% |
| Morgan Stanley | 4.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.71% |
Source: Nexqual, October 29, 2026 at 01:37 UTC.
From Structure Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- In total, our patent portfolio comprises over 480 patents and patent applications, as of December 31, 2025, filed in various jurisdictions worldwide.
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- Multiple approaches were applied for hit identification, including a screen of our proprietary incretin compound library.
- Our success also depends in part on our ability to operate without infringing the proprietary rights of others, and in part on our ability to prevent others from infringing our proprietary rights.
Partnerships
- In October 2020, Lhotse, our wholly-owned subsidiary, entered into a collaboration agreement with Schrödinger (the "Lhotse-Schrödinger Agreement") to discover and develop novel, orally bioavailable, small molecule inhibitors of LPA1R.
- In our partnership with Schrödinger on GPCR drug discovery, we retain the full product rights on the compounds under development.
Legal & Regulatory Risks (Item 1A, quoted)
- We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical studies or in obtaining marketing approval thereafter.
- Any difficulties or delays in the commencement or completion, or termination or suspension, of our ongoing and planned clinical studies could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
- We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such studies are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or applicable foreign authorities.
- Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 01:37 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt